Long-acting oral weekly risperidone (LYN-005) for schizophrenia in the USA (STARLYNG-1): a multicentre, open-label, non-randomised phase 3 trial

Journal:

The Lancet Psychiatry

Published:

2025-06-11

DOI:

10.1016/s2215-0366(25)00135-x

Affiliations:

6

Authors:

5

Go to article

Institutions	Authors	Share
Lyndra, United States of America (USA)	2.000000	0.40
Certara, United States of America (USA)	1.000000	0.20
New York Medical College (NYMC), United States of America (USA)	1.000000	0.20
Massachusetts Institute of Technology (MIT), United States of America (USA)	0.333333	0.07
Brigham and Women's Hospital (BWH), United States of America (USA)	0.333333	0.07
Broad Institute of MIT and Harvard, United States of America (USA)	0.333333	0.07

Interested in Clinical Sciences?